We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Vion Pharmaceuticals has filed a new special protocol assessment (SPA) with the FDA for a clinical trial of its acute myeloid leukemia (AML) treatment
Onrigin, following the agency’s rejection of an SPA for the drug earlier this month.